NEWAMSTERDAM PHARMA COMPANY N.V. ORDINARY SHARES
NASDAQ: NAMS (NewAmsterdam Pharma Company N.V)
Last update: 5 hours ago21.50
1.03 (5.03%)
| Previous Close | 20.47 |
| Open | 20.57 |
| Volume | 1,075,468 |
| Avg. Volume (3M) | 1,400,846 |
| Market Cap | 2,513,435,392 |
| Price / Earnings (Forward) | 119.05 |
| Price / Sales | 385.46 |
| Price / Book | 4.29 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2026 |
| Operating Margin (TTM) | -2,314.47% |
| Diluted EPS (TTM) | -1.84 |
| Quarterly Revenue Growth (YOY) | 112.60% |
| Total Debt/Equity (MRQ) | 0.05% |
| Current Ratio (MRQ) | 19.98 |
| Operating Cash Flow (TTM) | -140.43 M |
| Levered Free Cash Flow (TTM) | -99.00 M |
| Return on Assets (TTM) | -18.15% |
| Return on Equity (TTM) | -31.51% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | NewAmsterdam Pharma Company N.V | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 5.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Relative Valuation | NA |
| Financial Health | NA |
| AI Insight | NA |
| Weighted Average | 0.83 |
Select this tab to load the latest available analysis.
|
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Core |
| % Held by Insiders | 0.39% |
| % Held by Institutions | 111.32% |
AI Technical Analysis
Open the Technical tab to generate the latest analysis.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |